Chester County News and Community Website
Headquartered in Berwyn, PA, Annovis Bio, Inc. (NYSE: ANVS) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS).
MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) announced it will present two research updates on its investigational drug buntanetap at the 20th International Conference on Alzheimer’s and Parkinson’s Diseases, …
Annovis Bio to Present Buntanetap Clinical Data at AD/PD 2026 Conference Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) announced that an independent Data and Safety Monitoring Board has recommended continuation of its ongoing Phase 3 clinical trial of buntanetap in …
Malvern-Based Annovis Continues Phase 3 Alzheimer’s Trial After Safety Review Read More MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) said it will begin enrolling patients in January 2026 in a large, long-term study designed to assess whether its experimental Parkinson’s disease …
Annovis Launches 3-Year Parkinson’s Study to Test Long-Term Promise of Drug Read More MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) said it will host a corporate update webinar later this month as the clinical-stage biotechnology company moves into what it describes as …
Annovis Sets Investor Webinar as Neurodegeneration Pipeline Reaches Inflection Read More MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) unveiled new clinical data suggesting its investigational therapy buntanetap may reverse cognitive decline in Parkinson’s disease patients who also exhibit Alzheimer’s-related amyloid …
Parkinson’s Breakthrough? New Data Shows Drug May Reverse Cognitive Decline Read More MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) reported third-quarter 2025 financial results and detailed a series of clinical, operational, and intellectual-property developments that the company says position its lead …
Annovis Rallies Around Phase 3 Alzheimer’s Push as New Data Signals Disease-Modifying Promise Read More MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) announced that all 84 clinical sites in its pivotal Phase 3 study for early Alzheimer’s disease (AD) are now fully activated and …
Annovis Bio Reaches Key Milestone as Alzheimer’s Phase 3 Trial Gains Momentum Read More MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) announced new clinical findings indicating that its lead candidate, buntanetap, reduces inflammation and improves cellular health in patients with Alzheimer’s disease, suggesting …
Annovis Bio Reports Promising Biomarker Results Showing Anti-Inflammatory, Neuroprotective Effects of Buntanetap in Alzheimer’s Patients Read More MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) has appointed Mark Guerin, CPA, CMA, CFM, as Chief Financial Officer, bringing on a seasoned financial leader to guide the company through …
Annovis Bio Names Mark Guerin CFO as Buntanetap Nears Late-Stage Milestones Read More MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) announced the publication of a peer-reviewed article in Biomolecules detailing the pharmacokinetic profile of a newly developed crystal form of buntanetap, its …
Annovis Bio Publishes Data on New Crystal Form of Lead Alzheimer’s Drug Read More